title: Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients.
abstract: The epidermal growth factor receptor (EGFR) is one of the most appropriate target molecules for cancer therapy because of its high expression in epithelial cancers. A novel EGFR-tyrosine-kinase inhibitor, ZD1839, has been approved as a drug for non-small cell lung cancer (NSCLC), and many other agents are now being tested in clinical trials. Cytotoxic T lymphocyte (CTL)-directed epitope peptides could be another class of useful compounds in EGFR-targeted therapies. However, at present, there are no data on CTL-directed peptides of EGFR. Therefore, this study aimed to identify immunogenic EGFR-derived peptides in HLA-A24(+) NSCLC patients. We report in this study three such EGFR-derived peptides at positions 54-62, 124-132 and 800-809. These peptides were recognised by both cellular and humoral immune responses in most of the peripheral blood mononuclear cells (PBMCs) and sera from NSCLC patients that we tested. These results may provide a scientific basis for the development of EGFR-based immunotherapy.
authors.affiliation: Department of Immunology, School of Medicine, Research Center of Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University, 67 Asahi-machi, Kurume, Fukuoka 830-0011, Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Shomura
authors.forename: Shigeki
authors.initials: S
authors.lastname: Shichijo
authors.forename: Nobukazu
authors.initials: N
authors.lastname: Komatsu
authors.forename: Satoko
authors.initials: S
authors.lastname: Matsueda
authors.forename: Takashi
authors.initials: T
authors.lastname: Mine
authors.forename: Toru
authors.initials: T
authors.lastname: Rikimaru
authors.forename: Yuji
authors.initials: Y
authors.lastname: Sato
authors.forename: Satoru
authors.initials: S
authors.lastname: Todo
authors.forename: Kyogo
authors.initials: K
authors.lastname: Itoh
mesh_terms: D000917:Antibody Formation; D002289:Carcinoma, Non-Small-Cell Lung / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D066246:ErbB Receptors / Q000737:chemistry*; D015234:HLA-A Antigens / Q000276:immunology*; D059871:HLA-A24 Antigen; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007371:Interferon-gamma / Q000378:metabolism; D008175:Lung Neoplasms / Q000276:immunology*; D010455:Peptides / Q000032:analysis*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
chemical_list: D015234:HLA-A Antigens; D059871:HLA-A24 Antigen; D007074:Immunoglobulin G; D010455:Peptides; D007371:Interferon-gamma; D066246:ErbB Receptors